We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Quality Project to Evaluate and Validate the FAST-O Rating Scale (FAST-O)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00913731
Recruitment Status : Completed
First Posted : June 4, 2009
Last Update Posted : October 29, 2009
Sponsor:
Information provided by:

Study Description
Brief Summary:
The purpose of this project is to test the reliability of the FAST-O Rating Scale in patients at acute wards or psychiatric intensive care units.

Condition or disease
Acute Psychotic Symptoms

Study Design

Study Type : Observational
Actual Enrollment : 111 participants
Time Perspective: Prospective
Official Title: Quality Project to Evaluate and Validate the FAST-O Rating Scale (Fast ASessment in Acute Treatment of Psychosis-Observation)
Study Start Date : May 2009
Study Completion Date : October 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

Group/Cohort
psychotic patients
psychotic patients, acute ward, symptom rating scale.


Outcome Measures

Primary Outcome Measures :
  1. Reliability test of the FAST-O rating scale based on observational symptom ratings of patients with acute psychotic diseases [ Time Frame: Each patients symtoms will be rated on 2 occasions, by 2-3 raters, each. First is made within 24 hrs of admission to acute psychiatric care, secondis made 14 +/- 2 days after admittance, or earlier if the patient is discharged. ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with acute psychotic symptoms attending the acute ward or psychiatric intensive care unit
Criteria

Inclusion Criteria:

  • Patients with acute psychotic symptoms attending the acute ward or psychiatric intensive care unit

Exclusion Criteria:

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00913731


Locations
Sweden
Research Site
Helsingborg, Sweden
Research Site
Kristianstad, Sweden
Research Site
Lund, Sweden
Research Site
Malmo, Sweden
Research Site
Ystad, Sweden
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Eva Dencker Vansvik Medical Department
Principal Investigator: Eva Lindström Rättspsyk, UMAS, Malmö
More Information

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00913731     History of Changes
Other Study ID Numbers: NIS-NSE-DUM-2008/1
First Posted: June 4, 2009    Key Record Dates
Last Update Posted: October 29, 2009
Last Verified: October 2009

Keywords provided by AstraZeneca:
Psychotic symptom assessments
Observational assessments of patients with acute psychotic symptoms

Additional relevant MeSH terms:
Mental Disorders
Psychotic Disorders
Schizophrenia Spectrum and Other Psychotic Disorders